This company listing is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
MGC Pharmaceuticals 관리
관리 기준 확인 4/4
MGC Pharmaceuticals' CEO is Roby Zomer, appointed in Feb 2016, has a tenure of 7.75 years. total yearly compensation is A$354.02K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth A$18.77K. The average tenure of the management team and the board of directors is 2.8 years and 6.3 years respectively.
주요 정보
Roby Zomer
최고 경영자
AU$354.0k
총 보상
| CEO 급여 비율 | 100.0% |
| CEO 임기 | 7.8yrs |
| CEO 소유권 | 0.8% |
| 경영진 평균 재임 기간 | 2.8yrs |
| 이사회 평균 재임 기간 | 6.3yrs |
최근 관리 업데이트
Recent updates
CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2023 | AU$354k | AU$354k | -AU$21m |
| Mar 31 2023 | n/a | n/a | -AU$22m |
| Dec 31 2022 | n/a | n/a | -AU$23m |
| Sep 30 2022 | n/a | n/a | -AU$22m |
| Jun 30 2022 | AU$629k | AU$422k | -AU$20m |
| Mar 31 2022 | n/a | n/a | -AU$19m |
| Dec 31 2021 | n/a | n/a | -AU$18m |
| Sep 30 2021 | n/a | n/a | -AU$17m |
| Jun 30 2021 | AU$481k | AU$281k | -AU$16m |
| Dec 31 2020 | n/a | n/a | -AU$13m |
| Sep 30 2020 | n/a | n/a | -AU$16m |
| Jun 30 2020 | AU$440k | AU$290k | -AU$19m |
| Dec 31 2019 | n/a | n/a | -AU$18m |
| Sep 30 2019 | n/a | n/a | -AU$14m |
| Jun 30 2019 | AU$495k | AU$330k | -AU$11m |
| Dec 31 2018 | n/a | n/a | -AU$7m |
| Sep 30 2018 | n/a | n/a | -AU$7m |
| Jun 30 2018 | AU$498k | AU$334k | -AU$8m |
| Mar 31 2018 | n/a | n/a | -AU$10m |
| Dec 31 2017 | n/a | n/a | -AU$12m |
| Sep 30 2017 | n/a | n/a | -AU$10m |
| Jun 30 2017 | AU$783k | AU$233k | -AU$8m |
보상 대 시장: Roby's total compensation ($USD227.27K) is about average for companies of similar size in the Australian market ($USD295.83K).
보상과 수익: Roby's compensation has been consistent with company performance over the past year.
CEO
Roby Zomer (43 yo)
7.8yrs
테뉴어
AU$354,018
보상
Mr. Roby Reuven Zomer is a Co-Founder of MGC Pharmaceuticals Limited and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zomer has been Managing Director since May 2018...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | AU$354.02k | 0.76% A$ 18.8k | |
| Chief Accounting Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Deputy CEO & COO | 1.1yrs | 데이터 없음 | 0.39% A$ 9.5k | |
| Global Chief Sales Officer | 2.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Pharmaceutical Development Officer | no data | 데이터 없음 | 데이터 없음 | |
| Head of the Quality Assurance Department | 3.2yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | no data | 데이터 없음 | 데이터 없음 | |
| Deputy CEO | no data | 데이터 없음 | 데이터 없음 | |
| Chief Information Security Officer | no data | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Manufacturing & Supply Chain Officer | no data | 데이터 없음 | 데이터 없음 | |
| Chief Executive Officer of MGC Derma | 5yrs | 데이터 없음 | 데이터 없음 |
2.8yrs
평균 재임 기간
경험이 풍부한 관리: MXCDA's management team is considered experienced (2.8 years average tenure).
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | AU$354.02k | 0.76% A$ 18.8k | |
| Non-Executive Chairman & Senior Independent Director | 4.7yrs | AU$30.59k | 0.045% A$ 1.1k | |
| Chairman of Strategic Advisory Board & Independent Non-Executive Director | 7.8yrs | AU$44.00k | 0.11% A$ 2.8k | |
| Member of Strategic Advisory Board | 7.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | 5.3yrs | 데이터 없음 | 데이터 없음 |
6.3yrs
평균 재임 기간
경험이 풍부한 이사회: MXCDA's board of directors are considered experienced (6.3 years average tenure).